RDHL · Redhill Biopharma Ltd. American Depositary Shares
Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow RDHL by emailGet an email when RDHL pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about RDHL, unsubscribe in one click. Privacy
📣 What RDHL Says Is Next
this year · “We have designed a Phase 2 Proof-of-Concept study of RHB-102 for GLP-1/GIP receptor agonist therapy-associated GI side effects, planned to commence as early as possible this year.”
Company press release, Jan 5, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full RDHL picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for RDHL and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.